Abstract:Chimeric antigen receptors (CAR)-T cells are genetically engineered T-lymphocytes redirected with a predefined specificity to any target antigen, in a non-HLA restricted manner, therefore combining antibody-type specificity with effector T-cell function. This strategy was developed some thirty years ago, after extensive work established the key role of the immune system against cancer. The first-engineered T-cell with chimeric molecule was designed in 1993 by Israeli immunologist Zelig Eshhar. Since then, several modifications took place, including the addition of co-stimulatory domain, to further improve CAR-T cell anti-tumor potency. The first clinical application of CAR-T cell was done in Rotterdam in 2005 for metastatic renal cell carcinoma and simultaneously at the National Cancer Institute (NCI) for metastatic ovarian cancer. These pioneered studies failed to demonstrate a therapeutic benefit, but warning emerged concerning their safety of use. The real clinical success came with anti-CD19 CAR-T cells, used since 2009 by Steven Rosenberg at the NCI in a patient with refractory follicular lymphoma and in 2011 by Carl June and David Porter from the University of Pennsylvania in patients with chronic lymphocytic leukemia and B-cell acute lymphoblastic leukemia. From that time, large centers in North America have embarked in several early phase and pivotal trials that have demonstrated unprecedent response rate in heavily pretreated chemo refractory patient with B-cell malignancies. Theses clinical success have led to the approval of three anti-CD19 CAR-T cells products for the management of B-cell malignancies in the United States and in Europe as of December 2020.

In vivo CAR T cells move into clinical trials

Direct in vivo CAR T cell engineering

CAR T cells for treating autoimmune diseases

The Future of CAR T Therapeutics to Treat Autoimmune Disorders

Prospects for CAR T cell immunotherapy in autoimmune diseases: clues from Lupus

Application of CAR-T Cell Therapy beyond Oncology: Autoimmune Diseases and Viral Infections

CAR T cells: Building on the CD19 paradigm

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Tuning the performance of CAR T cell immunotherapies

CAR T therapy beyond cancer: the evolution of a living drug

Driving CAR T-cells forward

CAR T cell immunotherapy in hematology and beyond

Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms

Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment

The Unlikely Development of CAR T Cells: a Brief History and Prospects for the Future

In vivo engineering chimeric antigen receptor immune cells with emerging nanotechnologies

Treatment with Living Drugs: Pharmaceutical Aspects of CAR T Cells

CAR-T cells, from principle to clinical applications

Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer

CAR-T therapy for multiple sclerosis enters US trials for first time

CAR T Cells: A Snapshot on the Growing Options to Design a CAR